Paclitaxel in Treating Patients With Ovarian Stromal Cancer
NCT ID: NCT00006227
Last Updated: 2020-03-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
31 participants
INTERVENTIONAL
2000-11-20
2016-07-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00023907
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
NCT01042522
Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer
NCT00002928
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
NCT01468909
Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
NCT00005046
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To estimate the probability of clinical response and toxicity of paclitaxel as second-line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma.
II. To evaluate the value of inhibin for predicting response.
OUTLINE:
Patients receive paclitaxel intravenously (IV) over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, then every 6 months for three years, and then annually thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (paclitaxel)
Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
Paclitaxel
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Paclitaxel
Given IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have recurrent stromal tumor having received no more than one prior chemotherapy regimen
* Patients must have measurable disease as defined by Gynecological Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST) criteria
* White blood count equal to or greater than 3000/mcl
* Granulocyte count equal to or greater than 1500/mcl
* Platelet count equal to or greater than 100,000/mcl
* Creatinine equal to or less than 2.0 mg%
* Bilirubin less than or equal to 1.5 times normal
* Serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 3 times normal
* Patients with a GOG performance grade of 0, 1 or 2
* Patients of child bearing potential must have a negative pregnancy test and must agree to practice an effective means of birth control
* Patients who have met the pre-entry requirements as specified
* Patients must have signed an approved informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
Exclusion Criteria
* Patients with a prior invasive malignancy (except non-melanoma skin cancer) who have had any evidence of disease within the last 5 years or whose prior malignancy treatment contraindicates the current protocol therapy
* Patients having received more than one prior chemotherapy regimen
* Patients amenable to cure by surgery
* Patients with prior radiation except for those whose recurrent disease is outside the radiation port
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Gynecologic Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Linda Van Le
Role: PRINCIPAL_INVESTIGATOR
NRG Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Banner Thunderbird Medical Center
Glendale, Arizona, United States
Banner-University Medical Center Phoenix
Phoenix, Arizona, United States
Western Regional CCOP
Phoenix, Arizona, United States
Scottsdale Healthcare
Scottsdale, Arizona, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Long Beach Memorial Medical Center-Todd Cancer Institute
Long Beach, California, United States
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Community Hospital of Los Gatos
Los Gatos, California, United States
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States
UCSF Medical Center-Mount Zion
San Francisco, California, United States
North Colorado Medical Center
Greeley, Colorado, United States
McKee Medical Center
Loveland, Colorado, United States
Hartford Hospital
Hartford, Connecticut, United States
The Hospital of Central Connecticut
New Britain, Connecticut, United States
Beebe Medical Center
Lewes, Delaware, United States
Christiana Care Health System-Christiana Hospital
Newark, Delaware, United States
Memorial University Medical Center
Savannah, Georgia, United States
Rush - Copley Medical Center
Aurora, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
Sudarshan K Sharma MD Limted-Gynecologic Oncology
Hinsdale, Illinois, United States
Joliet Oncology-Hematology Associates Limited
Joliet, Illinois, United States
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
Saint Vincent Hospital and Health Care Center
Indianapolis, Indiana, United States
Franciscan Saint Anthony Health-Michigan City
Michigan City, Indiana, United States
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, United States
Norton Hospital Pavilion and Medical Campus
Louisville, Kentucky, United States
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
Medical Center of Baton Rouge
Baton Rouge, Louisiana, United States
Union Hospital of Cecil County
Elkton, Maryland, United States
Borgess Medical Center
Kalamazoo, Michigan, United States
Bronson Methodist Hospital
Kalamazoo, Michigan, United States
West Michigan Cancer Center
Kalamazoo, Michigan, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
Keesler Medical Center
Keesler Air Force Base, Mississippi, United States
Washington University School of Medicine
St Louis, Missouri, United States
Women's Cancer Center of Nevada
Las Vegas, Nevada, United States
Cooper Hospital University Medical Center
Camden, New Jersey, United States
Jersey Shore Medical Center
Neptune City, New Jersey, United States
State University of New York Downstate Medical Center
Brooklyn, New York, United States
Montefiore Medical Center-Einstein Campus
The Bronx, New York, United States
Montefiore Medical Center - Moses Campus
The Bronx, New York, United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Brookview Research Incorporated
Winston-Salem, North Carolina, United States
Novant Health Forsyth Medical Center
Winston-Salem, North Carolina, United States
Novant Health Oncology Specialists
Winston-Salem, North Carolina, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Aultman Health Foundation
Canton, Ohio, United States
University of Cincinnati/Barrett Cancer Center
Cincinnati, Ohio, United States
Case Western Reserve University
Cleveland, Ohio, United States
MetroHealth Medical Center
Cleveland, Ohio, United States
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Riverside Methodist Hospital
Columbus, Ohio, United States
Mount Carmel Health Center West
Columbus, Ohio, United States
Kettering Medical Center
Kettering, Ohio, United States
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio, United States
Lake University Ireland Cancer Center
Mentor, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma, United States
Abington Memorial Hospital
Abington, Pennsylvania, United States
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, United States
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
South Carolina Oncology Associates PA
Columbia, South Carolina, United States
Southeast Gynecologic Oncology Associates
Knoxville, Tennessee, United States
University of Tennessee Health Science Center
Memphis, Tennessee, United States
Brooke Army Medical Center
Fort Sam Houston, Texas, United States
Wilford Hall Medical Center
Lackland Air Force Base, Texas, United States
University of Virginia Cancer Center
Charlottesville, Virginia, United States
MultiCare Auburn Medical Center
Auburn, Washington, United States
Providence Regional Cancer System-Centralia
Centralia, Washington, United States
Saint Francis Hospital
Federal Way, Washington, United States
Saint Clare Hospital
Lakewood, Washington, United States
Providence - Saint Peter Hospital
Olympia, Washington, United States
Capital Medical Center
Olympia, Washington, United States
MultiCare Good Samaritan Hospital
Puyallup, Washington, United States
MultiCare Allenmore Hospital
Tacoma, Washington, United States
Northwest NCI Community Oncology Research Program
Tacoma, Washington, United States
West Virginia University Healthcare
Morgantown, West Virginia, United States
Tohoku University School of Medicine
Sendai, Aoba-ku, Japan
Sapporo Medical College
Sapporo, Chuo-ku, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Iwate Medical University School of Medicine
Morioka, Iwate, Japan
Kagoshima City Hospital
Kagoshima, Kagoshima-ken, Japan
Kawasaki Medical School
Okayama-Ken, Kurashiki, Japan
Keio University
Shinjuku-ku, Tokyo, Japan
National Hospital Organization-Kobe Medical Center
Kobe, , Japan
Shikoku Cancer Center
Matsuyama, , Japan
National Kyushu Cancer Center
Minamiku, , Japan
Jikei University School of Medicine
Minato-ku, Tokyo, , Japan
Kindai University
Osaka, Osaka, , Japan
Tottori University
Tottori, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2011-02054
Identifier Type: REGISTRY
Identifier Source: secondary_id
GOG #0187
Identifier Type: -
Identifier Source: secondary_id
CDR0000068149
Identifier Type: -
Identifier Source: secondary_id
GOG-0187
Identifier Type: -
Identifier Source: secondary_id
GOG-0187
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-0187
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-0187
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.